

Breakout session Education & Training

Chairs: Begonya Nafria Escalera & Mireille Muller

Education & Training



Accelerating Adoption of Complex Clinical Trials in Europe and beyond

5 - 6 OCTOBER 2021







Breakout session 6 Education & Training

Multi-stakeholder
workshop5 - 6 October 2021

Chairs: Begonya Nafria Escalera (eYPAGnet, ES) Mireille Muller (Novartis, EFPIA)

Having patients, regulators and HTA bodies, ethic committees, investigators and sponsors sufficiently familiarized with complex innovative clinical trials is essential for a healthy clinical research environment. This breakout session will provide a status update on available education and training material and identify training gaps regarding complex clinical trials. The session will help to assess the most pressing educational needs for the various stakeholders and start brainstorming on best suited organisations to provide such training and develop the necessary material/guidance.

House-keeping rules

(For active participants in the Zoom call)


- Mute your sound and video when not speaking



• Flag your intention to take the floor by raising your hand or by inputting your name into the Zoom-chat



• Introduce yourself (name, company, role) when taking the floor



You can scan the QR-code with your mobile device for direct access to the Q&A

Join our Q&A and online polls at

Slido.com #867 213

Direct link to our Q&A: https://app.sli.do/event/htnou5aw

Agenda

- Setting the scene
- Brief "tour de table":
 - Patients
 - Regulators
 - Ethic Committees
 - Health Technology Assessment (HTA) Bodies
 - Investigators
 - Sponsors
- Workshop questions
- Final thoughts/wrap up





BHC

Education and Training

Accelerating Adoption of Complex Clinical Trials in Europe and beyond

- Complex adaptive design trials increasingly
- Platform trials allow new research questions to be incorporated into an ongoing clinical trial protocol in structured way
- More efficient than opening new, separate trial
- UK Health Research Authority = ally to implementation of new and efficient designs.
- Few UK Research Ethics Committees exposed to platform protocols
- Therefore, HRA invited us to run 60--90 minutes workshops on adding a comparison to an ongoing platform trial protocol at 5 regional training meetings

Leicester (Sep-2019) York (Oct-2019) Oxford (Oct-2020) London (Feb-2020) Manchester (Mar-2020)

• Workshops involved:

- presentations on benefits & challenges of adding comparisons into ongoing protocols
- Guided group discussions on issues specific to ethics review

Question


What important aspects about

these trials that you would like to


have discussed?

Feedback for future meetings

 Training session attendees included some members of RECs who had reviewed a number of these platform protocols on previous occasions



V1 17-Sep-2019



Recommendations

- Initial Level of Review for Platform Trial Protocols
 - Trials that may add comparisons in future should explicitly flag this in protocol & on application forms at initial submission
- Level of Review for Amendment to Platform Trial
 - For more common reasons for protocol amendments, usual amendment route should suffice
 - When adding new comparison, triage amendment application to determine level of review REC feels is appropriate
 - eg if design & aims have not changed demonstrably, REC may prefer more limited review; otherwise, REC may prefer fuller review
- Information Required at Amendment to Support Triage
 - Should be clear what changes in amendment arise from addition of new comparison and what changes from other reasons

REVIEWING PLATFORM TRIAL PROTOCOLS: GUIDANCE FOR REC

01-Mar-2021

Professor Matthew Sydes, MRC Clinical Trials Unit at UCL Professor Louise Brown, MRC Clinical Trials Unit at UCL

ETTING

Complex skaptive design trials are becoming more common. Platform trials are a type of adaptive trial where new research questions (adled comparison) can be incorporated into an onpoing clinical trial protocol in a structured way. This is more practically efficient than opening a new, separate trial which would either compete for the same patients, hampering both trials, or delay one of the trials. The shaning of resources across comparisons brings efficiencies compared to separate protocols. Where appropriate, a shared control arm brings further efficiencies as these participants contribute to more than one comparison.⁴

The incorporation of a new comparison into an existing protocol can be done by amendment. This is simpler than a new application and means that the new comparison should be activated at sites more quickly than for a new, standalone trial, which should lead to faster initial recruitment.

Samples from MRC CTU at ULC of platform trial protocols that have added comparisons include: 1) <u>STAMPEDE</u>, a MANDS platform protocol is prostate cares: in which added comparisons involved the incorporation of a new research arm and extension of recruitment to a shared control arm. 2) <u>PCULSE</u>, a stratified medicine platform trial protocol in controctat clancer in which added comparisons involve the incorporation of both new research and control arms for a specified subset of astirst defined by a biometer iterature.

subset of patients defined by a biomarker signature (3) <u>RAMPART</u>, AMAMS platform protocol in renal cancer which has been designed with the intention of adding new comparisons

Examples in other disease areas include the <u>RECOVERY</u> and <u>PRINCIPLE</u> trials for treatment of the SAR-Cov-19 infection. These nationally prioritised studies needed to move at an unparalleled speed and may not set the precedent for other trials but the same principles apply to them.

DRKSHOPS

The Health Research Authority has been an ally to the implementation of new and efficient designs. New UR Research Chair Committes have been enoposed to platform portcools, but these will become increasingly common as the methods are embraced, NHFI, for example, has been during only officient designs and lists the platform protocol anoung them. Therefore, HAA insted Professors from and Sydes to run 60 to 90 minutes workshops on adding a comparison to an ongoing platform this protocol al five regional training meetings for Research EHsic committes in 2023 and 2020. These were held in Licester (Sep-2019), York (Dct-2019), Oxford (Oct-2020), London (Fe-2020) and Maximiset (Mar-2020).

The workshops involved presentations on the benefits and challenges of adding comparisons into ongoing protocols and guided group discussions on issues specific to ethics review. Training session attendees included some members of RECs who had reviewed a number of these platform protocols on previous occasions.

Short Report at www.ctu.mrc.ac.uk/medi a/1948/guidance_for_rec s_2021-03-01_v1.pdf

Home > About us > Committees and services > Research Ethics Service and Research Ethics Committees > Research Ethics Committee - Standard Operating Procedures Last updated on 2 Aug 2021

Under the UK Health Departments <u>Governance Arrangements for Research Ethics</u> <u>Committees (GAfREC)</u>, each <u>Research Ethics Committee (REC)</u> within the <u>Research</u> <u>Ethics Service</u>, is required to adopt Standard Operating Procedures (SOPs) approved by or on behalf of its appointing authority. The REC is required to act in accordance with its SOPs and is ultimately accountable to its appointing authority for its governance in this respect.

7.5.1 of the Standard Operating Procedures for Research Ethics Committees came into effect from 2

www.hra.nhs.uk/about-us/committeesand-services/res-and-recs/researchethics-committee-standard-operatingprocedures/

> www.ctu.mrc.ac.uk/ourresearch/methodology/conduct/practic al-implementation-of-new-trialdesigns/

News Our Research Studies Patients & Public Education & Capacity Building Careers

Reviewing platform protocols: Proposed guidelines for research ethics committees

(REC)

The review of platform protocols, both initially and at amendment is critically important. Sharing of information can be complex. Matt Sydes and Los Brown ran a series of regional workshops for REC members in the UK. which informed a report to the Health Research Authority (HRA). HRA's updated SOPs (due to be published Q2-2021) is expected to reflect these recommendations.

Read the short report

About

Hugh Davies, Research Ethics Advisor for HRA and chair of Oxford A REC, has written a blog entry on reviewing platform protocols, building out from our workshop recommendations, which can be found at the link below.



The Challenges of Running Platform Trials

The potential efficiencies of asking multiple questions in a single protocol are increasingly understood. This could b achieved using any or all of the following:

a multi-arm multi-stage (MAMS) design to ask multiple questions from the start
a platform (or Tiking) protocol to later add in new questions in a structured way
a biomark-rutatified designs for a within set multiple subsets of nations twith a shared screeering process.

Our new papers focus on the operational considerations in undertaking such designs, drawing particularly on MRC CTU at UCL's extensive experience with the STAMPEDE and FOCUS4 trials

The first paper by Schlavone et al focuses on issues that trial managers or trial coordinators might have in running the operational side of these trials.

The second paper by Hague et al focuses on issues that data managers, data scientists and programmers might have in running the operational side of these trials.

The third paper by Morrell et al draws out the experiences of central trials unit staff in running these trials.

REVIEWING PLATFORM TRIAL PROTOCOLS: GUIDANCE FOR RECS

01-Mar-2021

Professor Matthew Sydes, MRC Clinical Trials Unit at UCL Professor Louise Brown, MRC Clinical Trials Unit at UCL

ETTING

complex adaptive design traits are becoming more common. Flatform traits are a type of adaptive trail where new research questions (calido comparison) can be incorporated into a nogeng clinical trail porticol in a structured way. This is mere practically efficient than opening a new, separate traits which would effer complex for the same patterni, hingmering both Tusko, eddel one of the traits. Where appropriate, a shared control arm brings further efficiencies as these participants contribute to more than one comparison.¹⁴

The incorporation of a new comparison into an existing protocol can be done by amendment. This is simpler than a new application and means that the new comparison should be activated at sites more quickly than for a new, standalone trial, which should lead to faster initial recruitment.

Examples from MRC CTU at UCL of platform trial protocols that have added comparisons include: (U) STAMEDER: a MANG platform protocol in protate cancer in which added comparisons involved the incorporation of a new research arm and extension of recruitment to a shared control arm (2) FCULES, a straffed medicine platform trial protocol in corotact cancer in which added comparisons involve the incorporation of both new research and control arms for a specified subset of adjustment defined by a specified and adjustment of a specified subset of adjustment defined by a specified by the specifie

(3) <u>RAMPART</u>, a MAMS platform protocol in renal cancer which has been designed with the intention of adding new comparisons

Examples in other disease areas include the <u>BECOVEEP</u> and <u>PRINCIPE</u> trials for treatment of the SAR-Cov-19 infection. These nationally prioritised studies needed to move at an unparalleled speed and may not set the precedent for other trials but the same principles apply to them.

WORKSHOPS

The Health Besench Authority has been an ally to the imglementation of new rule officient designs, rev UK Resarch URIS Committes have been appoold o platemy protocols, but the well become increasingly common as the methods are embraced, NHR, for example, has been championg efficient designs and lists the uplatform protocol amoget them. Therefore, NBA invited Professore Brown and Sylets to run 60 to 90 minutes workshops on adding a comparison to an orgging platform that portocal at the regional training meetings of Resarch Efficie Committees in 2019 and 2020. These were held in Leicester (Sep 2019), York (Oct-2019), Oxford (Oct-2020), London (Feb-2020) and Manchester (Mor-2020).

The workshops involved presentations on the benefits and challenges of adding comparisons into ongoing protocols and guided group discussions on issues specific to ethics review. Training session attendees included some members of RECs who had reviewed a number of these platform protocols on previous occasions.

Short Report at www.ctu.mrc.ac.uk/medi a/1948/guidance_for_rec s_2021-03-01_v1.pdf

REVIEWING RESEARCH helping ensure better research for better health

Platform trials – a type of adaptive research

http://www.reviewingresearch.com/pl atform-trials/



Page under construction

Written after a report of recommendations from Matthew Sydes and Louise Brown (MRC Clinical Trials Unit at UCL) to Health Research Authority arising from a series of workshops they ran at HRA regional meetings in 2019 and 2020

Adaptive design trials accommodate the inevitable changes that happen during the lifetime of a study. One type is the platform trial which offers advantages but incorporates flexibility that needs to be considered in review. They incorporate new but similar research questions into an ongoing clinical trial protocol in a structured way. Put another way, the protocol includes or allows different comparisons. This paper explores the issues that might arise and how such proposals might be best reviewed.

Setting the scene

- Why is education & training important?
 - It is important to all stakeholders
 - Blagden et al. note that training is one of their key recommendations:
 - "the necessity to adapt the trial to emerging data and the inclusion of later-phase and site-specific cohorts means that CID trials require intense involvement from investigators. This requires a high level of PI and trial committee oversight, not only to review and assess their own patients but to participate in regular conference calls/communication with other centres and trial sponsors"
 - Informed stakeholders are better equipped to become actors in the design, implementation, organization and assessment of complex clinical trials (CCTs)

Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement (nature.com)





What is the current status?

CCTs scientific publications

オ specialised (inter-)national congresses or symposia

Useful material available in the closed communities?

Only limited information in the public domain







What is the current status?


CCTs scientific publications

specialised (inter-)national congresses or symposia

Useful material available in the closed communities?

Only limited information in the public domain


Huge gap between supply and demand






Accelerating Adoption of Complex Clinical Trials in Europe and beyond / 5 - 6 October 2021





Let's hear from the different parties



efpia

NF Patients

BHC

() Norwegian Medicines Agency



Accelerating Adoption of Complex Clinical Trials in Europe and beyond / 5 - 6 October 2021

Question 1

- Where is there a need for more targeted education?
 - Is this sufficient for e.g., Patients, investigators, sponsors what is still needed?
 - How difficult is it to find the right training?
 - How useful is the training? What metrics could be used?
 - How did the training help during the specific task? Was it fit for purpose?





Patients

- EUPATI or EURORDIS ACADEMY are good sources for basic information on clinical research in general
 - Insufficient resources for complex clinical trials available
 - When specialised knowledge is required, then it is difficult for patients to cope with the cost of expert training
 - A luxury that patient advocates and patient organisations can not afford!
- Experienced patient advocates working at international level can locate the right training
 - More challenging for national patient advocates





Regulators

- Some regulators developed in-house trainings, others attend conferences or workshops
- In most HAs, structured training is not yet available
 - Awareness is there
 - Experience is gained
 - "Learning by doing"





Ethics Committees (EC) 1/2

- Training for ethic committees even more challenging due to the diversity in membership, educational and professional members' background
 - Compostion varies, clinical staff (physicians, nurses, technicians), clinical trial methodologists, biostatisticians, pharmacists, ethicists, legal advisors, patient and human volunteer representatives, etc.
 - Very diverse knowledge of clinical trials, and even more so of complex clinical trials
- Currently no specific training is available
 - Mainly self-study and learning by doing





Ethics Committee (EC) 2/2

- Would need modular training for CCTs, treating general aspects, as well as targeted training towards specific subgroups of members
 - General high-level training for all

CCT: complex clinical trials EC: ethics committe

- Specialised training e.g., biostatistics training
- Specific training for patients and human volunteers in lay terms
- Some national EC-organisations have started working on training
 - Willingness to participate in European initiative to create an online toolbox with training material on CCTs ("train the trainer")





Health Technology Bodies (HTA)

- Training mainly by attending workshops & conferences
 - Professional societies such as ISPOR a good source of information
- Might be insufficient for complex clinical trials
- Some HTAs have interactions with regulators on this topic
 - But interaction doesn't mean alignment
 - Different assessment focus





Investigators & clinical staff

- Offers important opportunities for more junior researchers to learn about the delivery of clinical trials
- Inclusion into the curriculum of medical, nursing and pharmacology students would be desirable
- Ensuring access to appropriate continued or higher education on the topic
- Some governments have committed to programs to embed expert understanding on innovative trials







- Several sponsors have set up internal taskforces for the development of training on complex clinical trials and best practice sharing but it is *ad hoc* and not coordinated across different sponsors
- Although several sponsors actively participate in public private partnerships such as IMI or CTTI, these consortia do not appear to have a major focus on wide-scale education and training for CCTs. However, the set-up of these consortia do lend themselves to be in a good position to deliver an Education and Training programme that can be widely applicable
- Most commercial sponsor project teams should have sufficient access to subject matter experts in addition to general training
 - Peer coaching is also one avenue used especially for less frequently used designs
 - Training and coaching tend to be directed towards investigators and their staff who will be executing the trial
- Training and education tends to be specific for the trial to be conducted and, often, cannot be replicated across studies or between sponsors
- Experience sharing and common template helped to streamline and optimize the implementation and operations of complex clinical trials





R^{KC}

PPD^{*}

Question 2

- Who has to provide education and training for each of the stakeholders? (source of guidance)
 - Maintenance, update and sustainability
- Interest and feasibility of an EU-wide or international initiative?
- If an EC-EMA-HMA initiative on CCTs would be launched, delivery of E&T material should be part of it.






Question 3

• How to achieve common messaging across all the different guidelines?








BAC

What would be the vision for the future?




Final thoughts

- ICH E20's role in training & education
 - Unclear if training material is foreseen and might at best only available end of 2024





BFC



Pre-reads

- 1. EUPATI: EUPATI Open Classroom: All courses
- 2. Conferences like DIA, EFSPI etc.:
- 3. Blagden et al. Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement (nature.com)





BAC


Topics for discussion

- Where is there a need for more targeted education?
 - Is currently available training sufficient for e.g., Patients, investigators, sponsors
 - what is still needed?
 - How difficult is it to find the right training?
 - How useful is the training? \rightarrow would be metrics useful?
 - How did it help during the specific task? \rightarrow Is available training fit for purpose?
- Who should provide education and training for each of the stakeholders? (source of guidance)
 - Who should ensure maintenance, updates and sustainability?
- How to achieve common messaging across the different guidelines?





How to go back to the plenary session?



As a viewer

Click on the "home" and "Watch Live" respectively in the navigation and find the continued plenary session and click on "Live".



As an active participant

Close the zoom session of your breakout session and go back to the webinar platform and chose the continued plenary session. If you are an active speaker, panelist or moderator, click the "Participate: Plenary" link.